<DOC>
	<DOCNO>NCT01641081</DOCNO>
	<brief_summary>The purpose Phase II study evaluate efficacy safety inhale formoterol fumarate Pressair DPI compare Foradil Aerolizer patient mild moderate asthma . This study include screen visit follow 4 month treatment period .</brief_summary>
	<brief_title>Efficacy Safety Study Compare Formoterol Fumerate Pressair DPI Foradil Aerolizer Patient With Mild Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Inclusions : Patients mildtomoderate asthma least 6 month prior Visit 1 ( define GINA Guidelines ) unlikely exacerbate study ( e.g. , due seasonal allergen exposure ) . Patients must stable dose Inhaled Corticosteroids ( ICS ) least 30 day prior Visit 1 . Patients combination ICS/LABA must discontinue use LABA must stable dose ICS 30 day prior Visit 1 . Qualifying spirometry Visit 1 demonstrate high FEV1 ≤ 85 % ≥ 60 % predicted age , height , gender use NHANES III ( NHANES 2010 ) bronchodilator medication withhold appropriate length time per List Concomitant Medications ( Appendix III ) Patient demonstrate reversibility increase FEV1 12 % 200 mL administration 360 µg albuterol . Highest predose FEV1 Visits 2 , 4 , 6 , 8 , 10 must within 25 % qualify FEV1 Visit 1 Exclusions : Patients clinically significant respiratory condition mild moderate asthma , COPD , active tuberculosis , history interstitial lung disease Patients severe asthma exacerbation require hospitalization previous 12 month Patient able withhold use inhale shortacting betaagonist ( SABA ) least 6 hour prior visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>